General practitioner consultation for postmenopausal bleeding after COVID-19 vaccination-a self-controlled cohort study.

IF 3.1 3区医学 Q2 PHARMACOLOGY & PHARMACY

British journal of clinical pharmacology Pub Date : 2025-03-18 DOI:10.1002/bcp.70045

Rana Jajou, Eugène P van Puijenbroek, Renee Veldkamp, Jetty A Overbeek, Florence P A M van Hunsel, Agnes C Kant

{"title":"General practitioner consultation for postmenopausal bleeding after COVID-19 vaccination-a self-controlled cohort study.","authors":"Rana Jajou, Eugène P van Puijenbroek, Renee Veldkamp, Jetty A Overbeek, Florence P A M van Hunsel, Agnes C Kant","doi":"10.1002/bcp.70045","DOIUrl":null,"url":null,"abstract":"Aims: The incidence of postmenopausal bleeding (PMB) has been increasing over the past years. Little is known about the risk of PMB after COVID-19 vaccination. Our study aimed to investigate this based on routine general practitioner (GP) healthcare data from the Netherlands.Methods: A retrospective self-controlled cohort study was performed, which included women aged ≥50 years who received at least 1 COVID-19 vaccination in 2021 and were registered in the GP databases of Nivel (the Nivel Primary Care Database, Nivel-PCD) or PHARMO by 1 January 2021. GP consultations for PMB in the exposed period (28 days after each COVID-19 vaccination) were compared with the nonexposed period (all-time outside the exposed period). Incidence rate ratios (IRRs) were calculated using Poisson regression, adjusting for SARS-CoV-2 infection during the study follow-up period.Results: A total of 692 760 COVID-19 vaccinated women aged ≥50 years were included. No increased GP consultations for PMB was observed for all COVID-19 vaccines together, as well as when stratifying the results by vaccine type (mRNA vs. vector) and vaccine brand (Pfizer/BioNTech, Moderna, AstraZeneca, Johnson & Johnson). After the second Moderna dose an adjusted IRR of 1.47 (95% confidence interval: 0.93-2.32) was observed and after the third Pfizer/BioNTech dose an adjusted IRR of 1.33 (95% confidence interval: 0.92-1.93); however, these results were not statistically significant.Conclusion: No increased number of GP consultations for PMB in primary care was observed after COVID-19 vaccination in general, nor for any of the COVID-19 vaccine brands, vaccine doses or potential risk groups.","PeriodicalId":9251,"journal":{"name":"British journal of clinical pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of clinical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/bcp.70045","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: The incidence of postmenopausal bleeding (PMB) has been increasing over the past years. Little is known about the risk of PMB after COVID-19 vaccination. Our study aimed to investigate this based on routine general practitioner (GP) healthcare data from the Netherlands.

Methods: A retrospective self-controlled cohort study was performed, which included women aged ≥50 years who received at least 1 COVID-19 vaccination in 2021 and were registered in the GP databases of Nivel (the Nivel Primary Care Database, Nivel-PCD) or PHARMO by 1 January 2021. GP consultations for PMB in the exposed period (28 days after each COVID-19 vaccination) were compared with the nonexposed period (all-time outside the exposed period). Incidence rate ratios (IRRs) were calculated using Poisson regression, adjusting for SARS-CoV-2 infection during the study follow-up period.

Results: A total of 692 760 COVID-19 vaccinated women aged ≥50 years were included. No increased GP consultations for PMB was observed for all COVID-19 vaccines together, as well as when stratifying the results by vaccine type (mRNA vs. vector) and vaccine brand (Pfizer/BioNTech, Moderna, AstraZeneca, Johnson & Johnson). After the second Moderna dose an adjusted IRR of 1.47 (95% confidence interval: 0.93-2.32) was observed and after the third Pfizer/BioNTech dose an adjusted IRR of 1.33 (95% confidence interval: 0.92-1.93); however, these results were not statistically significant.

Conclusion: No increased number of GP consultations for PMB in primary care was observed after COVID-19 vaccination in general, nor for any of the COVID-19 vaccine brands, vaccine doses or potential risk groups.

查看原文本刊更多论文

COVID-19疫苗接种后绝经后出血的全科医生咨询-一项自我对照队列研究

目的：绝经后出血（PMB）的发生率在过去几年中一直在增加。对COVID-19疫苗接种后PMB的风险知之甚少。我们的研究旨在基于荷兰的常规全科医生（GP）医疗保健数据来调查这一点。方法：采用回顾性自我对照队列研究，纳入年龄≥50岁、2021年至少接种1次COVID-19疫苗并于2021年1月1日前在Nivel的GP数据库（Nivel Primary Care Database, Nivel- pcd）或PHARMO中注册的女性。将暴露期（每次COVID-19疫苗接种后28天）与非暴露期（暴露期以外的所有时间）的PMB全科医生咨询进行比较。采用泊松回归计算发病率比（IRRs），调整研究随访期间SARS-CoV-2感染。结果：共纳入692 760名年龄≥50岁的COVID-19疫苗接种妇女。在按疫苗类型（mRNA vs. vector）和疫苗品牌（Pfizer/BioNTech、Moderna、AstraZeneca、Johnson & Johnson）对结果进行分层时，所有COVID-19疫苗的PMB就诊人数均未增加。第二次Moderna剂量后的调整IRR为1.47(95%可信区间：0.93-2.32)，第三次辉瑞/BioNTech剂量后的调整IRR为1.33(95%可信区间：0.92-1.93)；然而，这些结果没有统计学意义。结论：一般情况下，接种COVID-19疫苗后，初级保健机构中PMB的全科医生咨询数量没有增加，任何COVID-19疫苗品牌、疫苗剂量或潜在风险群体均没有增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British journal of clinical pharmacology 医学-药学

CiteScore

6.30

自引率

8.80%

发文量

419

审稿时长

1 months

期刊介绍： Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.